ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$5.06
0.15 (3.05%)
▲
5d:
+6.3%
30d:
+2.12%
90d:
-2.5%
BUY
HIGH Confidence
Analysis Updated: Apr 13, 2026 12:00 AM ET
Earnings: May 21, 2026
Smart Money Accumulation
ABEO is down 5.4% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 5,523 OI. Call ratio: 86% View Scanner →
Strength: 6.3/10
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.25
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.88
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $5.06, which is considered slightly high relative to its 30-day fair value range of $4.46 to $5.01. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.1) compared to its historical average (18.6). At these levels, the market is pricing in 4.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $5.25. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ABEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.57 (+286.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $5.25. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: ABEO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.57 (+286.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$4.46 -
$5.01
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.9%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 286.8% below Wall St target ($19.57)
- NEUTRAL: Market pricing in 4.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$4.46 -
$5.01
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.23
Resistance Level
$5.25
Current Trend
Sideways
Technical data as of
Apr 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.08
Wall Street Target
$19.57
(+286.8%)
Revenue Growth (YoY)
-100.0%
Profit Margin
1223.1%
Valuation Premium vs History
+4.2% premium
PE vs Historical
21.1 vs 18.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.2%
(market-implied from PE analysis)
1-Year Target
$5.27
(+4%)
2-Year Target
$5.49
(+9%)
3-Year Target
$5.72
(+13%)
3-Yr Target (if PE normalizes)
(PE: 21→19)
PE COMPRESSION
$5.05
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 4.86 | Current EPS (TTM): $1.01
Bull Case
$2.70
(-47%)
Analyst growth -50.0%, PE expands to 5.4
Base Case
$2.46
(-52%)
Market implied -50.0%, PE stable at 4.9
Bear Case
$3.34
(-34%)
Severe decline -20.0%, PE contracts to 4.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 13, 2026 7:32 PM ET
Data refreshes hourly during market hours. Next update: 8:32 PM
Data refreshes hourly during market hours. Next update: 8:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Crombez
SELL
16284 shares
2026-02-02
Leila Alland
SELL
18065 shares
2026-02-02
Mark Alvino
SELL
2000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1034 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$212 | 60 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$294 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 50 HOLD |
